December 13, 2019
It has been a tumultuous week in the realm of digital health partnerships. It started with word of Proteus Digital Health’s floundering business and failed investment round, which reports say was partially driven by cooling relations between the digital pill maker and its longtime patron Otsuka Pharmaceuticals. A few days later, Sanofi announced a company-wide strategy shift that found Onduo, its...
December 12, 2019
About eight month after its unveiling, Express Scripts has now revealed the companies and programs it is including in the inaugural cohort of its digital health formulary — the first such resource from a pharmacy benefits manager designed to help clients review vetted digital health programs.
The formulary is comprised of 15 clinically validated digital health programs addressing the management...
December 12, 2019
Amazon’s PillPack has struck a deal with Blue Cross Blue Shield of Massachusetts that integrates the former’s digital pharmacy platform into the payer’s MyBlue member app.
As part of the agreement Blue Cross members will have the option to switch their prescriptions over to PillPack directly from the MyBlue app without having to reenter their insurance details or medication list.
December 10, 2019
Sanofi announced a major strategy shift today that will end the pharma’s diabetes and cardiovascular R&D efforts in favor of a reinvigorated focus on growing its immunology and vaccine businesses.
Among the fallout of this new game plan is Onduo, the pharma’s diabetes management joint venture with Verily that the two companies invested $500 million into back in 2016, according to the company’...
December 9, 2019
Gainesville, Florida-based etectRx has received FDA 510(k) clearance for its ID-Cap System, a prescription ingestible system that sends adherence event logs to an external medical device.
Similar to the system pioneered by etectRx’s high-profile competitor, Proteus Digital Health, the ID-Cap’s core is a standard capsule containing a sensor that transmits a message once it comes into contact with...
December 9, 2019
Proteus Digital Health, maker of an ingestible sensor system for treatment adherence monitoring, was forced to furlough many of its employees last month after a $100 million funding round didn’t close as expected, according to a weekend report from CNBC.
These employees were brought back after about two weeks after Proteus was able to secure $5 million in emergency funding, according to the...
December 5, 2019
The FDA and National Institutes of Health are tapping the clinical community and a newly launched mobile platform in its search for novel infectious disease interventions.
Called CURE ID, the online data repository will allow clinicians to report instances in which existing FDA-approved drugs are used to successfully treat infections.
In particular, the tool captures clinical outcomes in cases...
December 3, 2019
AdhereTech’s smart pill bottle platform improved adherence and patient satisfaction among a small sample of multiple myeloma patients, according to a paper in the November issue of the Journal of Managed Care & Specialty Pharmacy.
This data has been roughly four years in the making, and stands the company’s first-ever peer-reviewed publication of adherence efficacy, AdhereTech CEO and...
(L to R) Andrew Hopper, Carson Pickens, Gilad Jacobs, Stacie Ruth, Grace Cordavano, and Kelly McKee discuss Patient Co-Creation last month at the Connected Health Conference in Boston. Photo by Jonah Comstock.
November 27, 2019
Healthcare stakeholders — from providers to payers to pharma and medical device companies — are more and more starting to include patients in the design process for new innovations and initiatives. But while that co-design is a good first step, it’s not enough, experts at the Connected Health Conference in Boston last month argued.
“Every health innovator wants to maximize their market success,”...
November 21, 2019
Welldoc is tapping Astellas Pharma to assist Japanese and Asian commercialization efforts for the former’s digital therapeutic for patients with diabetes, the companies announced yesterday.
To kick off the deal, Astellas is making an upfront $15 million payment to Welldoc, which will allow the pharma to jointly develop and commercialize the BlueStar product in the region. The two will also be...